吡非尼酮治疗特发性肺间质纤维化疗效Meta分析

被引：11

作者：

冯志红

魏兵

滕国杰

于春妮

聂秀红

机构：

[1] 首都医科大学宣武医院呼吸科

来源：

中国病案 | 2015年 / 16卷 / 05期

关键词：

吡非尼酮; 特发性肺间质纤维化; 疗效; Meta分析;

D O I：

暂无

中图分类号：

R563.9 [其他];

学科分类号：

100201 [内科学];

摘要：

目的评价吡非尼酮治疗特发性肺间质纤维化疗效。方法以"吡非尼酮"、"特发性肺间质纤维"、"pirfenidone"、"idiopathic pulmonary fibrosis"为关键词,检索Pub Med、Cochrane图书馆、EMbase、中国知网、万方数据库,筛选吡非尼酮治疗特发性肺间质纤维化的随机对照试验,检索日期为1999年1月至2014年12月。干预措施为吡非尼酮与安慰剂对照比较。结局指标主要终点事件是肺活量的改变量或用力肺活量占预计值百分比变化值,次要终点事件为疾病无进展生存期。使用Rev Man5.2软件进行Meta分析。结果共5项随机对照试验纳入Meta分析。与安慰剂组比较,用药组肺活量的改变量减小,差异有统计学意义[MD=0.08,95%CI(0.02,0.12),P=0.00005],吡非尼酮组肺活量下降幅度较少。用力肺活量占预计值百分比变化下降值,差异有统计学差异[OR=0.43,95%CI(0.28,0.64),P<0.00001],吡非尼酮组发生用力肺活量占预计值百分比下降的幅度较小,是保护因素。疾病无进展生存期差异有统计学差异[HR=0.57,95%CI(0.39,0.85),P<0.0001],吡非尼酮组可延缓特发性肺间质纤维化疾病进展,是保护因素。结论吡非尼酮能够延缓特发性肺间质纤维化患者肺功能下降,并且减缓疾病进展。

引用

页码：83 / 87

页数：5

共 8 条

[1]

LOW DOSE PIRFENIDONE SUPPRESSES TRANSFORMING GROWTH FACTOR BETA-1 AND TISSUE INHIBITOR OF METALLOPROTEINASE-1, AND PROTECTS RATS FROM LUNG FIBROSIS INDUCED BY BLEOMYCIN [J].

Xinlun Tian Wei Yao Zijian Guo Li Gu and Yuanjue ZhuDepartment of Respiratory Medicine Peking Union Medical College Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing .

ChineseMedicalSciencesJournal, 2006, (03) :145-151

[2]

Pirfenidone: A Novel Agent for the Treatment of Idiopathic Pulmonary Fibrosis [J].

Potts, Jason ;

Yogaratnam, Dinesh .

ANNALS OF PHARMACOTHERAPY, 2013, 47 (03) :361-367

[3]

Pirfenidone for the treatment of Hermansky–Pudlak syndrome pulmonary fibrosis.[J].Kevin O'Brien;James Troendle;Bernadette R. Gochuico;Thomas C. Markello;Jose Salas;Hilda Cardona;Jianhua Yao;Isa Bernardini;Richard Hess;William A. Gahl.Molecular Genetics and Metabolism.2011, 2

[4]

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials [J].

Noble, Paul W. ;

Albera, Carlo ;

Bradford, Williamson Z. ;

Costabel, Ulrich ;

Glassberg, Marilyn K. ;

Kardatzke, David ;

King, Talmadge E., Jr. ;

Lancaster, Lisa ;

Sahn, Steven A. ;

Szwarcberg, Javier ;

Valeyre, Dominique ;

du Bois, Roland M. .

LANCET, 2011, 377 (9779) :1760-1769

[5]

Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.[J].Hisashi Oku;Toshikatsu Shimizu;Tomoji Kawabata;Morio Nagira;Ichiro Hikita;Azumi Ueyama;Shuuichi Matsushima;Mikinori Torii;Akinori Arimura.European Journal of Pharmacology.2008, 1

[6]

Effect of pirfenidone on the pulmonary fibrosis of Hermansky–Pudlak syndrome.[J].William A Gahl;Mark Brantly;James Troendle;Nilo A Avila;Antonio Padua;Carlos Montalvo;Hilda Cardona;Karim Anton Calis;Bernadette Gochuico.Molecular Genetics and Metabolism.2002, 3

[7]

Pirfenidone suppresses tumor necrosis factor-α; enhances interleukin-10 and protects mice from endotoxic shock.[J].Hisashi Oku;Hitoshi Nakazato;Tatsuya Horikawa;Yuji Tsuruta;Ryuji Suzuki.European Journal of Pharmacology.2002, 1

[8]

A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level.[J].Hitoshi Nakazato;Hisashi Oku;Shoji Yamane;Yuji Tsuruta;Ryuji Suzuki.European Journal of Pharmacology.2002, 1

← 1 →